Incyte マネジメント

マネジメント基準チェック /34

Incyteの CEO はHerve Hoppenotで、 Jan2014年に任命され、の在任期間は 10.92年です。の年間総報酬は$ 16.66Mで、 7.8%給与と92.2%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.2%を直接所有しており、その価値は€ 24.55M 。経営陣と取締役会の平均在任期間はそれぞれ8.9年と7.9年です。

主要情報

Herve Hoppenot

最高経営責任者

US$16.7m

報酬総額

CEO給与比率	7.8%
CEO在任期間	10.9yrs
CEOの所有権	0.2%
経営陣の平均在職期間	8.9yrs
取締役会の平均在任期間	7.9yrs

経営陣の近況

Recent updates

CEO報酬分析

Incyte の収益と比較して、Herve Hoppenot の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	US$32m
Jun 30 2024	n/a	n/a	US$97m
Mar 31 2024	n/a	n/a	US$745m
Dec 31 2023	US$17m	US$1m	US$598m
Sep 30 2023	n/a	n/a	US$425m
Jun 30 2023	n/a	n/a	US$366m
Mar 31 2023	n/a	n/a	US$324m
Dec 31 2022	US$17m	US$1m	US$341m
Sep 30 2022	n/a	n/a	US$876m
Jun 30 2022	n/a	n/a	US$945m
Mar 31 2022	n/a	n/a	US$933m
Dec 31 2021	US$14m	US$1m	US$949m
Sep 30 2021	n/a	n/a	US$535m
Jun 30 2021	n/a	n/a	US$338m
Mar 31 2021	n/a	n/a	US$478m
Dec 31 2020	US$16m	US$1m	-US$296m
Sep 30 2020	n/a	n/a	-US$335m
Jun 30 2020	n/a	n/a	-US$191m
Mar 31 2020	n/a	n/a	-US$376m
Dec 31 2019	US$15m	US$1m	US$447m
Sep 30 2019	n/a	n/a	US$405m
Jun 30 2019	n/a	n/a	US$306m
Mar 31 2019	n/a	n/a	US$253m
Dec 31 2018	US$9m	US$996k	US$109m
Sep 30 2018	n/a	n/a	-US$109m
Jun 30 2018	n/a	n/a	-US$102m
Mar 31 2018	n/a	n/a	-US$167m
Dec 31 2017	US$16m	US$967k	-US$313m

報酬と市場: Herveの総報酬 ($USD 16.66M ) は、 German市場 ($USD 4.86M ) の同規模の企業の平均を上回っています。

報酬と収益: Herveの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Herve Hoppenot (64 yo)

10.9yrs

在職期間

US$16,659,526

報酬

Mr. Herve Hoppenot has been the Chairman of the Board at Incyte Corporation since May 2015 and as its Chief Executive Officer and was President since January 13, 2014 until June 05, 2023. Mr. Hoppenot serv...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Herve Hoppenot	CEO & Chairman	10.9yrs	US$16.66m	0.20% € 24.6m
Pablo Cagnoni	President and Head of Research & Development	1.6yrs	US$16.57m	0.00087% € 107.7k
Christiana Stamoulis	Executive VP & CFO	5.8yrs	US$5.08m	0.019% € 2.4m
Barry Flannelly	Executive VP & GM of North America	9.5yrs	US$4.09m	0.0062% € 767.7k
Steven Stein	Executive VP & Chief Medical Officer	9.8yrs	US$5.63m	0.0013% € 164.7k
Thomas Tray	VP of Finance	2.8yrs	データなし	0.0041% € 507.6k
Michael Morrissey	Executive VP & Head of Global Technical Operations	8.9yrs	データなし	0.019% € 2.3m
Ben Strain	Head of Investor Relations	no data	データなし	データなし
Sheila Denton	Executive VP	1.2yrs	データなし	0.0023% € 288.5k
Pamela Murphy	Vice President of Investor Relations & Corporate Communications	no data	データなし	データなし
Paula Swain	Executive Vice President of Human Resources	22.3yrs	US$1.31m	0.030% € 3.7m
Vijay Iyengar	Executive VP of Global Medical Affairs	no data	US$3.30m	0.0013% € 158.5k

8.9yrs

平均在職期間

60yo

平均年齢

経験豊富な経営陣: ICYの経営陣は経験豊富で経験豊富です（平均在職期間は8.9年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Herve Hoppenot	CEO & Chairman	10.9yrs	US$16.66m	0.20% € 24.6m
Jean-Jacques Bienaime	Independent Director	9.9yrs	US$478.76k	0.0080% € 995.5k
Julian Baker	Independent Lead Director	23.1yrs	US$512.76k	0.14% € 17.9m
Otis Brawley	Independent Director	3.3yrs	US$454.76k	0.0031% € 378.9k
Jacqualyn Fouse	Independent Director	7.9yrs	US$466.26k	0.0073% € 898.9k
Edmund Harrigan	Independent Director	5yrs	US$482.26k	0.0072% € 894.0k
Katherine High	Independent Director	4.8yrs	US$454.76k	0.0042% € 513.8k
Paul Clancy	Independent Director	9.9yrs	US$479.76k	0.0086% € 1.1m
Susanne Schaffert	Independent Director	2.2yrs	US$444.76k	0.0015% € 185.7k

7.9yrs

平均在職期間

64yo

平均年齢

経験豊富なボード: ICYの取締役会は経験豊富であると考えられます ( 7.9年の平均在任期間)。

企業分析と財務データの現状

データ	最終更新日（UTC時間）
企業分析	2024/12/20 10:03
終値	2024/12/20 00:00
収益	2024/09/30
年間収益	2023/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

* 米国証券を例とし、非米国証券については同等の規制書式と情報源を使用^。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら

分析モデルとスノーフレーク

このレポートの作成に使用した分析モデルの詳細は、Githubページでご覧いただけます。また、レポートの使用方法に関するガイドや、Youtubeでのチュートリアルもご用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Incyte Corporation 23 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、。アナリストの投稿は一日中更新されます。55

アナリスト	機関
Jasper Hellweg	Argus Research Company
Thomas Russo	Baird
Ishan Majumdar	Baptista Research

Incyte マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Insufficient new directors

Executive VP & Chief Medical Officer recently sold €644k worth of stock

Executive VP of Global Medical Affairs recently sold €1.0m worth of stock

Executive VP & GM of North America recently sold €1.1m worth of stock

Incyte Corporation, Annual General Meeting, Jun 12, 2024

Incyte Corporation Announces Executive Changes, Effective November 1, 2023

Recent updates

Incyte Announces Positive Results from Phase 3 Trial Evaluating Retifanlimab in Combination with Platinum-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer

Incyte Provides Update on Early Phase MRGPRX2 and MRGPRX4 Programs

Third quarter 2024 earnings released: EPS: US$0.55 (vs US$0.76 in 3Q 2023)

Incyte Corporation to Report Q3, 2024 Results on Oct 29, 2024

Insufficient new directors

Incyte 's Cdk2 Inhibitor Incb123667 Shows Promising Evidence of Clinical Activity in Patients with Advanced Solid Tumors, Notably Ovarian Cancer

Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®) in Relapsed or Refractory Follicular Lymphoma

Executive VP & Chief Medical Officer recently sold €644k worth of stock

Incyte and Syndax Pharmaceuticals Announce U.S. FDA Approval of Niktimvo™ (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD)

Second quarter 2024 earnings released: US$2.04 loss per share (vs US$0.91 profit in 2Q 2023)

Executive VP of Global Medical Affairs recently sold €1.0m worth of stock

Incyte Corporation to Report Q2, 2024 Results on Jul 30, 2024

Executive VP & GM of North America recently sold €1.1m worth of stock

Incyte Corporation (NasdaqGS:INCY) acquired Escient Pharmaceuticals, Inc. from a group of shareholders.

Incyte Corporation (NasdaqGS:INCY) announces an Equity Buyback for $1,672 million worth of its shares.

Incyte Corporation (NasdaqGS:INCY) announces an Equity Buyback for $1,672 million worth of its shares.

First quarter 2024 earnings released: EPS: US$0.76 (vs US$0.097 in 1Q 2023)

Incyte Corporation, Annual General Meeting, Jun 12, 2024

Incyte Corporation Maintains Earnings Guidance for 2024

Incyte Corporation (NasdaqGS:INCY) entered into a definitive agreement to acquire Escient Pharmaceuticals, Inc. from a group of shareholders for $750 million.

Incyte Corporation to Report Q1, 2024 Results on Apr 30, 2024

Incyte Announces New Results from A Phase 2 Study Evaluating the Efficacy and Safety of Twice-Daily Ruxolitinib Cream 1.5% (Opzelura®) in Adult Patients with Hurley Stage 1 or 2 (Mild-To-Moderate) Hidradenitis Suppurativa (HS)

Incyte Corporation Provides Earnings Guidance for 2024

Full year 2023 earnings released: EPS: US$2.67 (vs US$1.53 in FY 2022)

Incyte Corporation to Report Q4, 2023 Results on Feb 13, 2024

Incyte and Syndax Pharmaceuticals Present Additional Data from Positive AGAVE-201 Trial at ASH Plenary Session Showing Axatilimab Efficacy Including Durable Responses in Chronic Graft-Versus-Host Disease

Incyte Corporation Provides Earning Guidance for the Full Year 2023

Third quarter 2023 earnings released: EPS: US$0.76 (vs US$0.51 in 3Q 2022)

Incyte Announces New Data for Ruxolitinib Cream (Opzelura®) in Children with Atopic Dermatitis

Incyte Announces Positive 52-Week Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo

Incyte Corporation to Report Q3, 2023 Results on Oct 31, 2023

Incyte Corporation Announces Executive Changes, Effective November 1, 2023

Executive VP & Chief Medical Officer recently sold €1.2m worth of stock

Incyte Corporation Revises Earnings Guidance for the Year 2023

Second quarter 2023 earnings released: EPS: US$0.91 (vs US$0.73 in 2Q 2022)

Syndax Pharmaceuticals and Incyte Announce Positive Topline Results from the Pivotal Agave-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease

Incyte Corporation to Report Q2, 2023 Final Results on Aug 01, 2023

Incyte Corporation Appoints Pablo J. Cagnoni, M.D. as President and Head of Research & Development, Effective June 5, 2023

First quarter 2023 earnings released: EPS: US$0.097 (vs US$0.17 in 1Q 2022)

Incyte Announces 52-Week Results from Phase 2 Study Evaluating Povorcitinib (INCB54707) in Patients with Hidradenitis Suppurativa

Incyte Corporation Provides Earnings Guidance for the Year 2023

Full year 2022 earnings released: EPS: US$1.53 (vs US$4.30 in FY 2021)

Incyte Corporation to Report Q4, 2022 Results on Feb 07, 2023

Incyte Announces Data from Two LIMBER Studies Evaluating Combination Treatments in Patients with Myelofibrosis

Syndax Pharmaceuticals and Incyte Announce Axatilimab Phase 1/2 Data in Patients with Chronic Graft-Versus-Host Disease Published in the Journal of Clinical Oncology

Third quarter 2022 earnings released: EPS: US$0.51 (vs US$0.82 in 3Q 2021)

Incyte Corporation Announces Pivotal Phase 3 Data Showing Significant Improvements in Facial and Total Body Repigmentation with Ruxolitinib Cream (Opzelura™) in Vitiligo Published in New England Journal of Medicine

Incyte Corporation to Report Q3, 2022 Results on Nov 01, 2022

Incyte Announces the Appointment of Susanne Schaffert as New Member of Its Board of Directors

Incyte Corporation (NasdaqGS:INCY) entered into an agreement to acquire Villaris Therapeutics, Inc. from Medicxi Ventures (UK) LLP and others for $1.4 billion.

Incyte Corporation Announces FDA Approval Of Pemazyre® (Pemigatinib) As The First And Only Targeted Treatment For Myeloid/Lymphoid Neoplasms (MLNs) With FGFR1 Rearrangement

Second quarter 2022 earnings released: EPS: US$0.73 (vs US$0.68 in 2Q 2021)

Incyte Corporation Reaffirms Revenue Guidance for the Full Year 2022

Incyte Corporation Announces U.S. FDA Approval of Opzelura Cream for the Treatment of Vitiligo

Incyte Corporation to Report Q2, 2022 Results on Aug 02, 2022

FDA Approves Eli Lilly and Company and Incyte's OLUMIANT® (baricitinib) as First and Only Systemic Medicine for Adults with Severe Alopecia Areata

Chmp Recommends Approval of Eli Lilly and Company and Incyte's Olumiant® (Baricitinib) as the First and Only Centrally-Authorized Treatment for Adults with Severe Alopecia Areata (Aa)

FDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) for the Treatment of Certain Hospitalized Patients with COVID-19

Incyte Announces European Commission Approval of Jakavi (Ruxolitinib) as the First Post-Steroid Treatment for Acute and Chronic Graft-Versus-Host Disease

First quarter 2022 earnings released: EPS: US$0.17 (vs US$0.24 in 1Q 2021)

Incyte Corporation, Annual General Meeting, Jun 15, 2022

Incyte Announces Positive Committee for Medicinal Products Opinion for Capmatinib (Tabrecta®) for the Treatment of Metex14 Advanced Non-Small Cell Lung Cancer

Incyte Corporation to Report Q1, 2022 Results on May 03, 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Incyte Corporation Provides Revenue Guidance for the Full Year 2022

Incyte Announces Acceptance and Priority Review of SNDA for Ruxolitinib Cream (Opzelura) as a Treatment for Patients with Vitiligo

MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi®) in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Third quarter 2021 earnings released: EPS US$0.82 (vs US$0.069 loss in 3Q 2020)

Incyte Corporation (NasdaqGS:INCY) entered into stock purchase agreement to acquire 2.92% Syndax Pharmaceuticals, Inc. (NasdaqGS : SNDX) for $35 million.

マネジメント基準チェック /34